Reviewer's report

Title: Bevacizumab plus irinotecan improves both response and survival in patients with recurrent malignant glioma: a survival gain analysis

Version: 2 Date: 12 April 2010

Reviewer: Antonis Valachis

Reviewer's report:

I think that the authors have answered sufficiently to the major compulsory revisions. The title has changed and purpose of the study is more clearly defined. The article has modified adequately to systematic review. With this style and the changes, I think that this paper is appropriate for publication in BMC Cancer.

In my opinion, all tables should be in the full article and not as additional material because it's easier and more practical for the readers to have all information gathered in tables in full article. This can be considered as discretionary revision.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I declare that I have no competing interests